Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Isoniazid for Drug-Resistant Tuberculosis
NCT02236078Phase 1Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 2015
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isoniazid in Tuberculosis (TB), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Delta Colony Forming Units per ml per day at 6 days. Started Nov 2015; status: completed.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02236078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236078.